PDCD1 and non-small cell lung carcinoma: An increasing number of PD-1 inhibitors have been approved as first-line treatment of advanced NSCLC, and in clinical trials, these drugs have demonstrated superior efficacy relative to standard chemotherapy, providing clinicians with more treatment options.